Overview

Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the response rate to treatment with oxaliplatin and Navelbine in patients with previously treated NSCLC. Oxaliplatin and Navelbine have not been clinically evaluated yet. However, Navelbine has been safely administered with other platinum compounds.
Phase:
Phase 2
Details
Lead Sponsor:
Integrated Community Oncology Network
Collaborator:
Sanofi
Treatments:
Oxaliplatin
Vinorelbine